Author Archives: Deal With Cancer Team

Targetable FGFR2 ECD Gene Alterations in Solid Cancer

The discovery of oncogenic driver mutations and the subsequent developments in targeted therapies have led to improved outcomes for subsets of lung cancer patients. The identification of additional oncogenic and drug-sensitive alterations may similarly...